Karyopharm Therapeutics(KPTI) Prnewswire·2025-02-19 12:30Core Insights - Karyopharm Therapeutics reported total revenue of 113 million, showing slight growth compared to 2023 [5][18][19] - The company anticipates top-line data from the Phase 3 SENTRY trial in the second half of 2025 and aims to complete enrollment in the first half of 2025 [2][4] - Karyopharm has updated its Phase 3 XPORT-EC-042 trial for endometrial cancer, increasing the sample size to 276 and expecting top-line data in mid-2026 [4][10] Financial Performance - For the fourth quarter of 2024, total revenue was 33.7 million in the same quarter of 2023 [18] - U.S. net product revenue for Q4 2024 was 25 million in Q4 2023, indicating consistent demand for XPOVIO [5][19] - The company reported a net loss of 41.8 million in Q4 2023 [27][28] Research and Development Highlights - The Phase 3 SENTRY trial's co-primary endpoint has been updated to absolute mean change in total symptom score (Abs-TSS), with a sample size increase to approximately 350 patients [4][6] - In endometrial cancer, the trial will focus on TP53 wild-type tumors, which represent about 50% of all endometrial cancer cases [2][10] - Karyopharm continues to enroll patients in the Phase 3 XPORT-EC-042 trial and expects to pursue regulatory approval based on the strength of the data [10][14] Future Outlook - The company projects total revenue for 2025 to be between 155 million, with U.S. XPOVIO net product revenue expected to be between 130 million [16] - Karyopharm plans to maintain its commercial foundation in the competitive multiple myeloma market and drive increased revenues from XPOVIO [15] - The company aims to report preliminary data from the Phase 2 SENTRY-2 trial in the first half of 2025 and top-line results from the Phase 3 SENTRY trial in the second half of 2025 [15]